TRBN Trubion Pharmaceuticals (MM)

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the first quarter ended March 31, 2010, after the close of market on May 6, 2010. The company's earnings conference call will take place May 6, 2010 at 2 p.m. Pacific Time, 5 p.m. Eastern Time.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Both live events will be available for viewing on Trubion's website at http://investors.trubion.com.

First-Quarter 2010 Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, May 6, 2010

Trubion will host a conference call and webcast to discuss its first-quarter 2010 financial results. The call will be held May 6 at 2 p.m. PDT (5 p.m. EDT). The live event will be available on Trubion's website at http://investors.trubion.com/events.cfm, or by calling 1 (877) 564-1186 or 1 (973) 409-9686. A replay of the discussion will be available beginning the evening of May 6 on Trubion's website or by calling 1 (800) 642-1687 or 1 (706) 645-9291, and entering 71357019. The telephone replay will be available through May 13, 2010.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well as simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

TRBN-G

SOURCE Trubion Pharmaceuticals, Inc.